LP 109C2-5/11
Alternative Names: LP-109C2-5/11Latest Information Update: 15 Mar 2024
At a glance
- Originator Laminar Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 08 Mar 2024 Early research in Cancer in Spain (unspecified route) prior to February 2024 (Laminar Pharmaceuticals pipeline, February 2024)
- 08 Feb 2024 Laminar Pharmaceuticals plans to launch LP 109C2-5/11 in 2032 or 2033 (Laminar Pharmaceuticals pipeline, February 2024)